Avid Bioservices Inc (CDMO)

[biopharm]

Hakan Mellstedt : Peregrine Pharmaceuticals KOL :

I try to place any news related to the MOA of Bavi/PS Targeting from each of the 4 KOL's added Dec 10, 2013 (Dmitry Gabrilovich, David Carbone, Scott Antonia and Hakan Mellstedt) under each one.... and since I've already mentioned the book below authored by Dmitry, it does related directly over to Hakan Mellstedt and his research at Karolinska. Again, each KOL was strategically chosen and all will benefit by sort of being the latest of the chosen ones to have complete, up to date knowledge of why PS Targeting will be not just important... but simply vital for any immunotherapy to truly be called immunotherapy at all.

---------------------------------

1) Tumor-Induced Immune Suppression - Prospects and Progress in Mechanisms and Therapeutic Reversal

Author - Dmitry Gabrilovich 2nd Edition 2014

http://www.freshwap.me/5882240-tumor-induced-immune-suppression-mechanisms-and.html

-------------------------------------------------------------

2) We've seen these terms used many times: "Tumor-Induced Immune Suppression" and lets recall back in April of 2010 at AACR

New Preclinical Breast Cancer Study Shows Peregrine's PS-Targeting Antibodies Can Reverse Tumor-Induced Immune Suppression

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=461029

-------------------------------------------------------------

3) Now..again, these words are at the core of "Immunotherapy"... and lets start to connect them to Karolinska and Hakan Mellstedt

Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells

March 24, 2014 (yes... March Madness 2014)

Y. Mao1,
I. Poschke2 and
R. Kiessling1,*

Author Information

1 Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
2 German Cancer Research Center (DKFZ), Heidelberg, Germany

Abstract

Tumour-induced immune dysfunction is a serious challenge to immunotherapy for cancer, and intact adaptive and innate cellular immunity is key to its success. Myelomonocytic cells have a central role in this immune suppression, and tumour-associated macrophages, eosinophils, neutrophils and myeloid-derived suppressor cells have all been shown to be of major importance. These myelomonocytic cells secrete a broad repertoire of inflammatory mediators providing them with powerful tools to inhibit tumour-reactive T cells and natural killer cells; free oxygen radicals including reactive oxygen species and NO, arginase, indoleamine 2,3-dioxygenase, prostaglandins, the pro-inflammatory heterodimer S100A8/9 and cytokines, such as granulocyte–macrophage colony-stimulating factor and transforming growth factor-ß, have proven particularly potent in suppressing antitumour cellular immunity. Determining which of these factors prevail in individual cancer patients and designing methods aimed at neutralization or inhibition of their effects on target tissues have the potential to greatly enhance the clinical efficacy of immunotherapy.

http://onlinelibrary.wiley.com/doi/10.1111/joim.12229/abstract

------------------------------------------------------

4) Rolf Kiessling's Group

Members and group leaders in IMTAC are;


Håkan Mellstedt, Cancercenter Karolinska, Karolinska Institutet.

Ola Winqvist, Department of Medicine, Karolinska Institutet

Klas Kärre, Microbiology and Tumor Biology Center, Karolinska Institutet

Kalle Malmberg, Department of Medicine, Karolinska Institutet

Annika Scheynius, Department of Medicine, Karolinska Institutet.

Petter Höglund, Microbiology and Tumor Biology Center, Karolinska Institutet


Additional examples of collaborators at Karolinska Institutet


Giuseppe Masucci, Cancer Centrum Karolinska, Karolinska Institutet

Johan Hansson, Cancer Centrum Karolinska, Karolinska Institutet

Katarina Le Blanc, Clinical Immunology, Karolinska Institutet

Kalle Malmberg, Centre of Infectious Medicine, Karolinska Institutet

Lars Holmgren, Cancer Centrum Karolinska, Karolinska Insitutet

Olle Larsson, Cancer Centrum Karolinska, Karolinska Institutet

Stefan Seregard, St. Erik Eye Hospital, Karolinska Institutet

Tina Dalianis, Cancer Centrum Karolinska, Karolinska Insitutet


External collaborators


Andrew Quest, University of Chile, Santiago, Chile

Barbara Seliger, Martin-Luther University, Halle-Wittenberg, Germany

Brahm H. Segal, Roswell Park Cancer Institute, University of Buffalo, USA

Federica Cavallo, University of Turin, Italy

Flavio Salazar-Onfray, University of Chile, Santiago, Chile

Göran Stenman, University of Gothenburg, Sweden

Guido Forni, University of Turin, Italy

Jehad Charo, Max-Delbruck Center for Molecular Medicine Berlin, Germany

Koji Kono, Yamanashi Medical University, Yamanashi, Japan

Kousako Mimura, Yamanashi Medical University, Yamanashi, Japan

Michael I. Nishimura, Medical University of South Carolina, USA

Takashi Ando, Yamanashi Medical University, Yamanashi, Japan

Wei-Zen Wei, Karmanos Cancer Center, Wayne State University, USA


Collaborators in Industry

BioInvent International AB, Sweden
Cyto-Pulse Science, Inc, Stockholm, Sweden
Mabtech AB, Nacka, Sweden
Philochem AG, Switzerland
Protagen AG, Dortmund, Germany
ThromboGenics NV, Belgium


-------------------------------------------------

http://www.researchgate.net/profile/Isabel_Poschke



Isabel Poschke
Rolf Kiessling

ABSTRACT Myeloid-derived suppressor cells (MDSC) have frequently been observed in patients with cancer. This heterogeneous population of myeloid cells can exert potent suppression of lymphocyte function and thereby poses a significant hurdle to natural or therapeutically induced anti-tumor immunity. On the other hand, the natural function of MDSC is not yet well understood and their role in infection, inflammation and autoimmune disease is still puzzling. Understanding MDSC biology will provide the tools necessary for therapeutic targeting of this population, but also permit exploitation of their strong tolerogenic function in the treatment of inflammatory conditions and the prevention of graft rejection.

http://www.researchgate.net/publication/230615237_On_the_armament_and_appearances_of_human_myeloid-derived_suppressor_cells

-------------------------------------------------------

There are still, even more puzzle pieces that off shoot from all these above leading into/out of Karolinska, but one thing is for sure: MDSC's and the Notch Signaling pathway and all those cascade of events that take place ( that I've mostly placed under KOL Dmitry Gabrilovich's link of posts ) are all parts of the sum that explain why/how the MOA of Bavituximab and one day, hopefully soon... Peregrine is allowed to tell all. We certainly will not be a sub $2 stock at that time.